611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO, CA
Reports Second Quarter 2026 Financial Results and Recent Highlights
Directors Elected at Structure Therapeutics Inc. Annual General Meeting
Reports First Quarter 2026 Financial Results and Recent Highlights
Annual Report to Security Holders
Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
Topline ACCESS II and Supplementary Studies
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Material Agreement with Genentech for GLP-1 Receptor Agonists
Q2
Q1
FY 2025
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report